-
-
-
-
-
-
-
Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Stifel on Summit Therapeutics plc (SMMT): 'first look, ever, at an emerging OS from an invonescimab P3 randomized against antiPD-1 (tislelizumab)'
-
-
-
-
-
-
-
Jefferies Downgrades Summit Therapeutics plc (SMMT) to Hold
-
-
-
-
-
-
-
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab
-
-
-
-
-
-
-
Ivonescimab shows survival benefit in lung cancer study
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet
-
-
-
-
-
-
-
Summit presents lung cancer trial data at ESMO 2025
-
413,528 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

